This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/drugbank/
n9http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/national-drug-code-directory/
n27http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/chebi/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/wikipedia/
n15http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/pharmgkb/
n21http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00943/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00943
rdf:type
n3:Drug
n3:description
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. [PubChem]
n3:generalReferences
# Shelton MJ, O'Donnell AM, Morse GD: Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8097417 # Devineni D, Gallo JM: Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May;28(5):351-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 7614775
n3:group
approved
n3:halfLife
2 hours
n3:indication
For the treatment of Human immunovirus (HIV) infections in conjunction with other antivirals.
n3:manufacturer
n9:271B3FA3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00943 n27:DB00943
dcterms:title
Zalcitabine
adms:identifier
n6:Zalcitabine n10:PA451950 n12:24066 n13:D00412 n14:0004-0220-01 n17:46507879 n20:10101 n22:C07207 n23:22498 n24:DB00943
n3:mechanismOfAction
Zalcitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Within cells, zalcitabine is converted to its active metabolite, dideoxycytidine 5'-triphosphate (ddCTP), by the sequential action of cellular enzymes. ddCTP interferes with viral RNA-directed DNA polymerase (reverse transcriptase) by competing for utilization of the natural substrate deoxycytidine 5'-triphosphate (dCTP), as well as incorpating into viral DNA. Due to it's lack of a 3'-OH group, the formation of a 5' to 3' phosphodiester linkage that is necessary for DNA chain elongation is inhibited, thus leading to the termination of viral DNA growth.
n3:packager
n9:271B3FA1-363D-11E5-9242-09173F13E4C5 n9:271B3FA2-363D-11E5-9242-09173F13E4C5 n9:271B3FA0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Renal excretion of unchanged drug appears to be the primary route of elimination, accounting for approximately 80% of an intravenous dose and 60% of an orally administered dose within 24 hours after dosing (n=19). Renal clearance exceeds glomerular filtration rate suggesting renal tubular secretion contributes to the elimination of zalcitabine by the kidneys.
n3:synonym
Dideoxycytidine 4-amino-1-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one DDC DDCYD 2',3'-Dideoxycytidine
n3:toxicity
Acute overdose: Inadvertent pediatric overdoses have occurred with doses up to 1.5 mg/kg zalcitabine. Chronic overdose: in an initial dose-finding study in which zalcitabine was administered at doses 25 times (0.25 mg/kg every 8 hours) the currently recommended dose, one patient discontinued zalcitabine after 1½ weeks of treatment subsequent to the development of a rash and fever.
n3:volumeOfDistribution
* 0.304 to 0.734 L/kg
n3:foodInteraction
Take on empty stomach: 1 hour before or 2 hours after meals. Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
n3:proteinBinding
Less than 4%
n15:hasConcept
n16:M0024532
foaf:page
n19:zalcitabine.html n21:zalcit.htm
n3:IUPAC-Name
n4:271B3FAA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3FB0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3FAF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3FAC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3FAD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3FAE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3FC0-363D-11E5-9242-09173F13E4C5 n4:271B3FA8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3FA6-363D-11E5-9242-09173F13E4C5 n4:271B3FA9-363D-11E5-9242-09173F13E4C5 n4:271B3FC2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3FA7-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:J05AF03
n3:H-Bond-Acceptor-Count
n4:271B3FB6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3FB7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3FB1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3FB2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3FB4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3FB3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3FB5-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is over 80% following oral administration.
n3:affectedOrganism
Human Immunodeficiency Virus
n3:casRegistryNumber
7481-89-2
n3:category
n3:clearance
* 285 mL/min [HIV-infected patients receiving 1.5 mg IV infusion for 1 hour]
n3:containedIn
n28:271B3FA4-363D-11E5-9242-09173F13E4C5 n28:271B3FA5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3FBC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3FBE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3FBF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3FC1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3FBB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3FBA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3FBD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3FAB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3FB8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3FB9-363D-11E5-9242-09173F13E4C5